Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4249 trials
Conditions Burnout Syndrome, Anxiety Depression, St...
Phase NA
Enrollment 180
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Burnout is a common problem among healthcare professionals and may affect their psychological well-being, quality of life, and professional functioning. This study will examine whether an intensive compassion-based intervention can help reduce burnout and improve well-being in healthcare professionals. Participants will be randomly assigned to either an Attachment-Based Compassion Therapy intervention or a relaxation intervention. Outcomes will be measured before the intervention, immediately after the intervention, and three months later. Attachment-Based Compassion groups will be composed of 80 participants each, and TAU group will be composed of 80 participants (total sample n = 160). Burnout Inventory-Human Services Survey - MBI-HSS. Burnout will be assessed using the Maslach Burnout Inventory-Human Services Survey. This questionnaire evaluates the three main dimensions of burnout: emotional exhaustion, depersonalization, and personal accomplishment. Items are rated on a Likert-type scale according to the frequency with which the participant experiences each symptom. Scores are calculated separately for each burnout dimension. In this study, emotional exhaustion and depersonalization will be considered the primary outcome variables, while reduced personal accomplishment will be considered a secondary outcome variable

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: Double

Interventions / Regimen

  • Behavioral: Attachment-based compassion therapy Compassion — Program consists of 8 session of 120 minutes/session (15-20 people) Written material andsound recordings will be offered as support elements. The estimated duration of the program is one weekend
  • Behavioral: Relaxation program — Relaxation program consists of 8 sessions of 120 minutes/session (15-20 people) Written material and sound recordings will be offered as support elements. The estimated duration of the program is one weekend

Primary Outcomes

  • MASLACH BURNOUT INVENTORY HUMAN SERVICES SURVEY (MBI-HSS) (Baseline)
  • MASLACH BURNOUT INVENTORY HUMAN SERVICES SURVEY (MBI-HSS) (baseline)
  • MASLACH BURNOUT INVENTORY HUMAN SERVICES SURVEY (MBI-HSS) (Post-treatment 1 weekend from baseline)
  • MASLACH BURNOUT INVENTORY HUMAN SERVICES SURVEY (MBI-HSS) (Post-treatment 1 weekend from baseline)
  • MASLACH BURNOUT INVENTORY HUMAN SERVICES SURVEY (MBI-HSS) (Three-months follow-up])
  • MASLACH BURNOUT INVENTORY HUMAN SERVICES SURVEY (MBI-HSS) (Three-months follow-up])
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-09-10
Completion: 2028-04-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 180 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Hospital Miguel Servet
Contact Information
Study Contact:
Javier García Campayo, PhD
+34976506578
jgarcamp@gmail.com
Miguel Servet University Hospital
Interventions
  • Behavioral: Attachment-based compassion therapy Compassion — Program consists of 8 session of 120 minutes/session (15-20 people) Written material andsound recordings will be offered as support elements. The estimated duration of the program is one weekend
  • Behavioral: Relaxation program — Relaxation program consists of 8 sessions of 120 minutes/session (15-20 people) Written material and sound recordings will be offered as support elements. The estimated duration of the program is one weekend
Study Locations (1 sites)
Miguel Servet University Hospital, Zaragoza, Spain 50009 Spain
Eligibility Criteria
Inclusion Criteria: 1. Active healthcare professionals (physicians and nurses) of both sexes. 2. Understanding of spoken and written Spanish. 3. Availability of a computer and internet connection. 4. Written informed consent. Exclusion Criteria: * Previous psychological treatment within the last year, or current psychological treatment. Presence of a severe uncontrolled medical, infectious, or degenerative disease that may interfere with affective symptoms. Presence of a mental disorder related to substance dependence/abuse, or any other disease affecting the central nervous system. Suicide risk, defined as a score of ≥2 on item 9 of the PHQ-9. Scheduled surgical intervention during the course of the study.
Conditions Type 1 Diabetes Mellitus, T1D, Type 1 Di...
Phase EARLY_PHASE1
Enrollment 40
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This research study is testing an investigational dual-port insulin patch pump that integrates a continuous glucose monitor (CGM) in adults with type 1 diabetes. The goal of the study is to better understand how insulin delivery near a CGM sensor affects glucose readings and to collect data to support development of a combined insulin pump and CGM system. People with type 1 diabetes require lifelong insulin therapy. Many use insulin pumps and CGMs, but these systems usually involve wearing multiple devices at different body sites. Managing several devices can increase treatment burden and may contribute to skin irritation, device failures, and challenges with glucose control. This study is conducted in two in-patient parts. In Part A, participants will wear three investigational devices at the same time while glucose levels are closely monitored using laboratory blood tests and a commercial CGM. This part of the study is designed to measure how basal and bolus insulin delivery near the CGM sensor affects sensor accuracy and how quickly the sensor signal recovers after insulin delivery. In Part B, participants will wear one investigational device while trained study staff use CGM information from the integrated sensor to guide insulin delivery recommendations generated by an automated glucose control algorithm. Insulin delivery decisions will be closely supervised, and glucose levels will be frequently monitored. Participants will stay at the clinical research center for short, controlled study visits. Safety will be monitored throughout the study, with predefined procedures for treating low or high blood sugar. The information collected will be used to support further development of an integrated insulin pump and CGM system for people with type 1 diabetes.

Design

Study type: Interventional Phases: Early Phase1 Allocation: Intervention model: Sequential Primary purpose: Other Masking/blinding: None

Interventions / Regimen

  • Device: DPP System (Insulin Pump and Continuous Glucose Monitoring Platform) — Participants will use the DPP System, an integrated insulin pump and continuous glucose monitoring-based device, during inpatient study visits. The system will be evaluated under multiple study conditions, including sensor characterization procedures and automated glycaemic control during standardized meals and exercise.

Primary Outcomes

  • Maximum post-bolus difference between DPP CGM sensor glucose and YSI plasma glucose (During Part A clamp period (Day 2; approximately 09:00-17:00), assessed after each bolus.)
  • Time to maximum post-bolus difference between DPP CGM sensor glucose and YSI plasma glucose (During Part A clamp period (Day 2; approximately 09:00-17:00), assessed after each bolus.)
  • Time to full recovery of DPP CGM sensor signal following bolus insulin delivery (During Part A clamp period (Day 2; approximately 09:00-17:00), assessed after each bolus.)
  • Percent of DPP CGM sensor values meeting 20/20 agreement criteria vs reference glucose (Part A in-patient period (Day 1 to Day 2), with primary comparison during the clamp and intensive monitoring period.)
  • Percent time in glucose ranges based on Dexcom G7 (Time in Range / Time Below / Time Above) (Part B in-patient period (approximately 2.5 days; Day 1 and Day 2, and combined across Part B).)
  • Mean absolute relative difference (MARD) of DPP CGM vs reference glucose (Part B in-patient period (Day 1 and Day 2, and combined across Part B).)
  • Mean absolute deviation (MAD) of DPP CGM vs reference glucose by basal rate (Part B in-patient period (Day 1 and Day 2, and combined across Part B).)
  • Bias of DPP CGM vs reference glucose by basal rate (Part B in-patient period (Day 1 and Day 2, and combined across Part B).)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: Recruiting
Start Date: 2026-05-19
Completion: 2026-12-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 40 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: ClinSurge Research
Collaborators: McGill University Health Centre/Research Institute of the McGill University Health Centre, PharmaSens AG, Biel/Bienne Switzerland
Contact Information
Study Contact:
Karri Venn, BSc
647 274 4133
karri.venn@clinsurge.ca
Eden Stein, B.Sc, M.Sc, MBA
416 688 0813
eden.stein@clinsurge.ca
Eden Stein, B.Sc, M.Sc, MBA
416 688 0813
eden.stein@clinsurge.ca
ClinSurge Research
Interventions
  • Device: DPP System (Insulin Pump and Continuous Glucose Monitoring Platform) — Participants will use the DPP System, an integrated insulin pump and continuous glucose monitoring-based device, during inpatient study visits. The system will be evaluated under multiple study conditions, including sensor characterization procedures and automated glycaemic control during standardized meals and exercise.
Study Locations (1 sites)
ClinSurge Research, Toronto, Ontario M4G 3E8 Canada
Eligibility Criteria
Inclusion Criteria Part A: * Males and females ≥ 18 years of age. * Clinical diagnosis of type 1 diabetes for at least 12 months. The diagnosis of type 1 diabetes is based on the investigator's judgment; C peptide level and antibody determinations are not needed. * Undergoing multiple daily injection or continuous subcutaneous insulin infusion therapy for at least 3 months. Those using an automated insulin delivery system can also participate. * Total daily insulin dose (TDD) between 30 and 100 IU. Inclusion Criteria Part B: * Males and females ≥ 18 years of age. * Clinical diagnosis of type 1 diabetes for at least 12 months. The diagnosis of type 1 diabetes is based on the investigator's judgment; C peptide level and antibody determinations are not needed. * Undergoing continuous subcutaneous insulin infusion therapy for at least 3 months. Those using an automated insulin delivery system can also participate. * Totally daily insulin dose (TDD) between 30 and 100 IU. Exclusion Criteria (A and B): * Serious medical illness likely to interfere with study participation or with the ability to complete the trial by the judgment of the investigator. * Failure to comply with the study protocol or with the team's recommendations. * Current or recent use of any anti-hyperglycemic agent other than insulin (≤ one month for GLP1-RA, ≤ one week for all others). * Female participants of childbearing potential who are pregnant, breastfeeding, or unwilling to use effective contraception during the study. Pregnancy will be verified by urine dipstick testing at the time of admission visit. * Severe hypoglycemic episode within one month of admission. * Severe diabetic ketoacidosis episode within one month of admission. * Clinically significant nephropathy, neuropathy or retinopathy as judged by the investigator. * Recent (\<6 months) acute macrovascular event e.g., acute coronary syndrome or cardiac surgery. * Other serious medical illness likely to interfere with study participation or with the ability to complete the trial by the judgment of the investigator. * Current or ≤ one month use of supraphysiological doses of systemic glucocorticoids * Pronounced lipohypertrophy in the abdominal subcutaneous adipose tissue, which may impair sensor function or insulin infusion. * Insufficient abdominal surface area to support the wearing of three DPP systems in Part A.
Conditions Asthma
Phase PHASE3
Enrollment 514
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The study aims to demonstrate the superiority of GSK5784283 compared to placebo in reducing the annualized rate of clinically meaningful asthma exacerbations.

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Drug: GSK5784283 — GSK5784283 will be administered.
  • Drug: Placebo — Placebo will be administered.
  • Drug: Standard of care — Standard of care will be administered.

Primary Outcomes

  • Annualized rate of clinically significant asthma exacerbations (Up to Week 52)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2026-08-27
Completion: 2029-10-11
Eligibility
Age: 12 Years and older
Sex: ALL
Volunteers: false
Enrollment: 514 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: GlaxoSmithKline
Principal Investigators:
  • GSK Clinical Trials (STUDY_DIRECTOR) - GlaxoSmithKline
Contact Information
Study Contact:
US GSK Clinical Trials Call Center
877-379-3718
GSKClinicalSupportHD@gsk.com
EU GSK Clinical Trials Call Center
+44 (0) 20 89904466
GSKClinicalSupportHD@gsk.com
US GSK Clinical Trials Call Center
877-379-3718
GSKClinicalSupportHD@gsk.com
GSK Investigational Site
Interventions
  • Drug: GSK5784283 — GSK5784283 will be administered.
  • Drug: Placebo — Placebo will be administered.
  • Drug: Standard of care — Standard of care will be administered.
Study Locations (1 sites)
GSK Investigational Site, Miami Lakes, Florida 33014-2479 United States
Eligibility Criteria
Inclusion Criteria: * Participants capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in Informed consent form (ICF). For participants aged 12 to 17 years, signed assent must be obtained from the participant in addition to signed consent from their Legally acceptable representative (LAR). * Participants aged 12 to 80 years at the time of signing the informed consent. * Male or eligible female participants: * Female participants: * A female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least 1 of the following conditions applies: i. Is a Participant of non-childbearing potential (PONCBP) or ii. Is a Participant of childbearing potential (POCBP) and using a contraceptive method that is highly effective, with a failure rate of less than (\<) 1 percent (%), 28 days prior to the first dose of the study drug, and during the study intervention period and follow-up period for at least 60 weeks after the last dose of study intervention. The investigator should evaluate potential for contraceptive method failure (e.g., non-compliance, recently initiated) in relationship to the first dose of study intervention. * A POCBP must have a negative serum pregnancy test at screening and a highly sensitive pregnancy test (urine or serum, as required by local regulations) within 24 hours before each dose of study intervention. * If a urine test cannot be confirmed as negative (e.g., an ambiguous result), a serum pregnancy test is required. In such cases, the participant must be excluded from participation if the serum pregnancy result is positive. * The investigator is responsible for review of medical history, menstrual history, and recent sexual activity to decrease the risk for inclusion of a woman with an early undetected pregnancy. * Contraceptive use by women should be consistent with local regulations regarding the methods of highly effective contraception for those participating in clinical trials. * A documented physician diagnosis of asthma for at least 12 months prior to Visit 1, according to the Global Initiative for Asthma (GINA) 2026 guidelines. * Evidence of variable airflow obstruction consistent with asthma. * Documented history of asthma exacerbation within 12 months prior to Visit 1. * A well-documented requirement for regular treatment with medium or high dose Inhaled corticosteroid (ICS) for at least 3 months prior to screening with or without maintenance oral corticosteroids (OCS). * At least 1 additional maintenance asthma controller medication is required according to standard practice of care (e.g., Long-acting beta-2 agonist \[LABA\], Leukotriene receptor antagonists \[LTRA\], theophylline, Long-acting muscarinic agonists \[LAMA\], chromones, etc.). Use of additional asthma controller medications must be documented for at least 3 months prior to screening. * Uncontrolled asthma based on ACQ-5 score. Exclusion Criteria: * Any concomitant respiratory disease that in the opinion of the investigator and/or medical monitor will interfere with the evaluation of the investigational product or interpretation of participant safety or study results. * History of malignant neoplasm within the last 5 years (except definitively treated non-melanoma skin cancer or carcinoma in situ of the uterine cervix). * Myocardial infarction, unstable angina or stroke within 6 months of screening, unstable arrhythmia. * New York Heart Association (NYHA) class III or IV heart failure. * Other significant medical conditions that could impact participants' safety or study outcomes. * History of an unresolved clinically significant infection within 30 days prior to Visit 1. * A known immunodeficiency, other than that explained by the use of corticosteroids taken as therapy for asthma. * Receipt of any marketed or investigational biologic agent or investigational non-biologic agent, prior to Visit 1. * Use of systemic immunosuppressive medication within 3 months prior to Visit 1 (other than systemic corticosteroid burst or stable maintenance OCS for treatment of asthma). * Current smokers (tobacco and/or marijuana), current users of vaping products/electronic-cigarettes or participants with a smoking history \>=10 pack-years.
Conditions Chronic Pain
Phase Not Applicable
Enrollment 20
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to investigate the relationship between alexithymia levels and clinical parameters, including pain intensity and quality of life, in chronic pain patients treated with spinal cord stimulation (SCS). Chronic neuropathic pain can lead to psychological distress and decreased quality of life. While SCS is an effective neuromodulation therapy for managing refractory pain, patient outcomes vary significantly, suggesting that biomedically similar patients experience different levels of relief due to psychosocial factors. Alexithymia, characterized by difficulties in identifying and describing emotions, may significantly influence the individual pain experience and treatment outcomes. In this cross-sectional observational study, patients who underwent SCS implantation for clinical indications will be evaluated. Clinical data regarding pain history will be collected retrospectively from patient files, while psychosocial profiles will be assessed at a single time point using validated psychometric questionnaires. The study aims to contribute to a better understanding of psychosocial variables in neuromodulation outcomes, potentially aiding in improved patient selection and expectation management.

Design

Study type: Observational Observational model: Other Time perspective: Cross Sectional

Interventions / Regimen

  • Other: Psychometric Questionnaires and Retrospective Data Collection — Participants are evaluated at a single time point using self-report questionnaires including the Toronto Alexithymia Scale (TAS-20), Hospital Anxiety and Depression Scale (HADS), Short Form Health Survey (SF-12), and Childhood Trauma Questionnaire (CTQ-33). Pain intensity (VAS/NRS) and clinical data are extracted retrospectively from medical records.

Primary Outcomes

  • Toronto Alexithymia Scale (TAS-20) Score (Baseline)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2026-06-01
Completion: 2027-06-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 20 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Marmara University
Contact Information
Study Contact:
Osman Hakan Gunduz, Prof. MD
02166570606
ipek98uyanik@gmail.com
Marmara University Pendik Training and Research Hospital
Interventions
  • Other: Psychometric Questionnaires and Retrospective Data Collection — Participants are evaluated at a single time point using self-report questionnaires including the Toronto Alexithymia Scale (TAS-20), Hospital Anxiety and Depression Scale (HADS), Short Form Health Survey (SF-12), and Childhood Trauma Questionnaire (CTQ-33). Pain intensity (VAS/NRS) and clinical data are extracted retrospectively from medical records.
Study Locations (1 sites)
Marmara University Pendik Training and Research Hospital, Istanbul, Turkey (Türkiye)
Eligibility Criteria
Inclusion Criteria: * \- Being 18 years of age or older * Having undergone permanent spinal cord stimulation (SCS) implantation due to clinical indications * Providing written informed consent for study participation * Being literate * Having the cognitive capacity to complete the psychometric scales * No active, severe psychiatric disorders requiring immediate treatment (e.g., schizophrenia, bipolar affective disorder, severe psychotic disorders) Exclusion Criteria: * Cognitive impairment or communication barriers that compromise the capacity to provide informed consent * Presence of active psychotic disorders or manic episodes * Suspected self-harm or suicide risk during the clinical interview * Presence of specific secondary causes that could explain the pain (e.g., active malignancy, active infection, acute fracture)
Conditions Asthma Acute, COPD Exacerbation Acute
Phase PHASE2
Enrollment 40
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

A Phase 2, open-label, single-arm trial to evaluate IV rademikibart as an add-on treatment for acute exacerbation in participants with asthma or COPD with type 2 inflammation

Design

Study type: Interventional Phases: Phase2 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Rademikibart — Single 300 mg dose as a 2-minute IV push

Primary Outcomes

  • Change from baseline in post-BD FEV1 (1 week)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2026-08-21
Completion: 2027-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 40 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Connect Biopharm LLC
Contact Information
Study Contact:
Radha Adivikolanu
213-522-7990
clinical209@connectpharm.com
Radha Adivikolanu
213-522-7990
clinical209@connectpharm.com
Columbus Clinical Services, LLC
Radha Adivikolanu
213-522-7990
clinical209@connectpharm.com
Pharmax Research of South Florida, Inc.
Interventions
  • Drug: Rademikibart — Single 300 mg dose as a 2-minute IV push
Study Locations (2 sites)
Columbus Clinical Services, LLC, Miami, Florida 33135 United States
Pharmax Research of South Florida, Inc., Miami, Florida 33175 United States
Eligibility Criteria
Inclusion Criteria - Asthma cohort * Body weight of ≥40 kg and BMI ≤45 kg/m2 at SV1a. * Physician-diagnosed asthma * Currently receiving treatment with low, medium, to high dose ICS in combination with at least 1 additional asthma controller medication. * Must have experienced at least 1 asthma exacerbation requiring the use of systemic corticosteroids. * Participants in a stable condition, must have a historical peripheral blood eosinophil count of ≥250 cells/μL and/or FeNO ≥ 25 ppb. * Current acute asthma exacerbation requiring an urgent healthcare visit for treatment. * Peripheral blood eosinophil count of ≥300 cells/µL as part of the assessment of an index acute asthma exacerbation. * Requires systemic corticosteroid as SoC in the urgent healthcare setting to treat the current acute asthma exacerbation. * FEV1 ≥30% predicted. Exclusion Criteria - Asthma cohort * Regular use of immunosuppressive medication. * Unstable ischemic heart disease, cardiomyopathy, heart failure, uncontrolled hypertension. * Current or former smoker, with a smoking history of ≥5 pack-years if \<30 years old or ≥10 pack-years if ≥30 years old * COPD and other clinically significant pulmonary disease other than asthma. * Known or suspected history of immunosuppression. * History of known immunodeficiency disorder or hepatitis B or C. * History of alcohol abuse and/or drug abuse. * Recent history of cancer except basal cell carcinoma or in situ carcinoma of the cervix or other malignancies treated with apparent success with curative therapy. * Female participant who is pregnant, lactating or breast-feeding. * Recent receipt of any marketed nonbiologic drug that modulates type 2 cytokines. * Recent receipt of any marketed biologic drug or any investigational biologic for asthma or other diseases. * Recent live, attenuated vaccinations or planned live, attenuated vaccinations during the trial. * Participants that have been recently treated with bronchial thermoplasty. * Recent receipt of any investigational nonbiologic drug. * A recent chest X-ray or computed tomography with findings that are inconsistent for an asthmatic population. Inclusion Criteria - COPD cohort * Body weight of ≥45 kg and BMI ≤45 kg/m2 * Physician-diagnosed COPD * Must have experienced at least 1 COPD exacerbation requiring the use of systemic corticosteroids. * Participants in a stable condition must have a historical peripheral blood eosinophil count of ≥250 cells/μL and/or FeNO ≥ 25 ppb. * Current or former smoker with a history of smoking of ≥10 pack-years. * Current acute COPD exacerbation requiring an urgent healthcare visit for treatment. * Peripheral blood eosinophil count of ≥300 cells/μL as part of the assessment of the index acute COPD exacerbation. * Requires systemic corticosteroids as standard of care treatment in the urgent healthcare setting for the current acute COPD exacerbation. Exclusion Criteria - COPD cohort * Regular use of immunosuppressive medication 12 weeks or 5 half-lives prior to approximately 12 weeks or 5 half-lives, whichever is longer. * Current diagnosis or a history of asthma, according to the Global Initiative for Asthma; or participants with a current diagnosis or history of Asthma COPD Overlap Syndrome. * Other respiratory disorders that might compromise the safety of the participant or affect the interpretation of the results. * Unstable ischemic heart disease, cardiomyopathy, heart failure, uncontrolled hypertension. Cardiac arrhythmias including paroxysmal atrial fibrillation. * Transient ischemic attack or stroke \<6 months from Screening Visit; hospitalization for any cardiovascular or cerebrovascular event \<6 months from Screening Visit. * Known or suspected history of immunosuppression. * History of known immunodeficiency disorder or hepatitis B or C. * History of alcohol abuse and/or drug abuse. * Recent history of cancer except basal cell carcinoma or in situ carcinoma of the cervix treated with apparent success. * Chronic treatment with long-term oxygen therapy or nocturnal oxygen therapy required for \>15 hours a day. * Participants on long-term macrolide. * Current acute COPD exacerbation for which SoC was started \>48 hours prior to Screening. * A recent chest X-ray or computed tomography scan reveals evidence of clinically significant abnormalities or pulmonary infection. * Female participant who is pregnant, lactating or breast-feeding. * Receipt of any marketed nonbiologic drug that modulates type 2 cytokines 30 days or 5 half-lives prior to SV1b, whichever is longer. * Receipt of any marketed or any investigational biologic for COPD or other diseases within 16 weeks or 5 half-lives, whichever is longer. * Live, attenuated vaccinations within 4 weeks prior to screening or planned live, attenuated vaccinations during the trial. The above inclusion and exclusion criteria are not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Conditions Cancer Screening, Lung Cancer, Breast Ca...
Phase NA
Enrollment 1500
Locations 3 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study will evaluate whether a precision navigation intervention can help community residents at high risk for cancer complete recommended cancer screening. The study will be conducted in communities participating in an urban cancer screening program in China. Eligible participants will be adults aged 45 to 74 years who are permanent residents of participating communities and have been identified as being at high risk for at least one of five cancers: lung cancer, breast cancer, colorectal cancer, upper gastrointestinal cancer, or liver cancer. Participants must not have completed the corresponding free clinical screening before enrollment. This is a dual-cohort, cluster randomized controlled trial. Communities, rather than individual participants, will be assigned to one of three groups: a precision navigation group, a usual health education group, or a waiting control group. Participants will be classified into two cohorts according to the number of cancers for which they are assessed as high risk. Cohort A will include participants at high risk for three or more cancers, and Cohort B will include participants at high risk for one or two cancers. Participants in the precision navigation group will receive a personalized navigation report matched to their risk profile. The report will explain the screening tests most relevant to them, help them understand screening choices, and provide practical steps to support screening completion. Participants in the usual health education group will receive general cancer screening education materials. Participants in the waiting control group will not receive active screening promotion during the main intervention period, but will receive general education materials after the primary assessment. The main outcome is whether participants complete the recommended cancer screening during follow-up. The study will also assess changes in screening-related decision conflict, anxiety, self-efficacy, and behavioral intention. The results may help improve community-based cancer screening programs and provide evidence for using personalized navigation strategies to increase screening participation among high-risk populations.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Screening Masking/blinding: None

Interventions / Regimen

  • Behavioral: Precision Navigation Intervention — Participants in the precision navigation group will receive a personalized navigation report based on their cancer risk profile from the urban cancer screening program. The report will be tailored according to whether the participant is at high risk for three or more cancers or for one or two cancers. It will provide individualized information on high-risk cancer types, recommended screening tests, screening procedures, common barriers to screening, and practical action steps. Trained staff will provide a brief standardized explanation of the report and support participants in making a screening action plan.
  • Behavioral: Usual Health Education — Participants in the usual health education group will receive general cancer screening education materials. The materials will provide basic information about cancer prevention, early detection, and screening for lung cancer, breast cancer, colorectal cancer, upper gastrointestinal cancer, and liver cancer. The content is not personalized according to the participant's individual risk profile.

Primary Outcomes

  • Proportion of Participants Completing Recommended Cancer Screening (From enrollment to 6 months after enrollment)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-08-04
Completion: 2027-06
Eligibility
Age: 45 Years and older
Sex: ALL
Volunteers: true
Enrollment: 1500 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Hunan Cancer Hospital
Contact Information
Study Contact:
Haifan Xiao
8615580869827
xiaohaifan@hnca.org.cn
Qiang Yan
8615111549588
383114173@qq.com
Huaihua Central Hospital (Huaihua Cancer Hospital)
Liping Deng
8618473926876
Shaoyang Hospital of Traditional Chinese Medicine
Interventions
  • Behavioral: Precision Navigation Intervention — Participants in the precision navigation group will receive a personalized navigation report based on their cancer risk profile from the urban cancer screening program. The report will be tailored according to whether the participant is at high risk for three or more cancers or for one or two cancers. It will provide individualized information on high-risk cancer types, recommended screening tests, screening procedures, common barriers to screening, and practical action steps. Trained staff will provide a brief standardized explanation of the report and support participants in making a screening action plan.
  • Behavioral: Usual Health Education — Participants in the usual health education group will receive general cancer screening education materials. The materials will provide basic information about cancer prevention, early detection, and screening for lung cancer, breast cancer, colorectal cancer, upper gastrointestinal cancer, and liver cancer. The content is not personalized according to the participant's individual risk profile.
Study Locations (3 sites)
Huaihua Central Hospital (Huaihua Cancer Hospital), Huaihua, Hunan China
Shaoyang Hospital of Traditional Chinese Medicine, Shaoyang, Hunan China
Yongzhou Central Hospital, Yongzhou, Hunan China
Eligibility Criteria
Inclusion Criteria: 1. Aged 45 to 74 years. 2. Permanent resident of a participating community, defined as having lived in the community for at least 6 months during the past 12 months. 3. Participating in the urban cancer screening program. 4. Identified by the program risk assessment questionnaire as being at high risk for at least one of the following cancers: lung cancer, breast cancer, colorectal cancer, upper gastrointestinal cancer, or liver cancer. 5. Has not yet completed the corresponding free clinical screening test for the high-risk cancer type or types. 6. Able to complete electronic questionnaires and read intervention materials independently or with assistance. Paper materials and staff explanation will be provided for participants who do not use smartphones. 7. Able and willing to provide written informed consent. Exclusion Criteria: 1. Previously diagnosed with any of the target cancers, including lung cancer, breast cancer, colorectal cancer, upper gastrointestinal cancer, or liver cancer. 2. Severe cognitive impairment, severe mental illness, or other conditions that prevent the participant from receiving the intervention or completing study questionnaires. 3. Planning to be away from the community for a long period during the next 6 months, defined as cumulative absence of more than 3 months. 4. Currently participating in another interventional study that may affect cancer screening behavior.
Conditions Asthma (Diagnosis), COPD (Chronic Obstru...
Phase Not Applicable
Enrollment 200
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study aims to improve the diagnosis and treatment prediction of asthma and chronic obstructive pulmonary disease (COPD) by combining quantitative chest computed tomography (CT) imaging with multi-omics data. Adults with asthma or COPD will be enrolled and undergo routine clinical evaluations, pulmonary function tests, blood tests, and chest CT scans. Additional samples, such as sputum and microbiome specimens, may also be collected. No experimental drugs or devices will be administered as part of this study. Researchers will analyze CT imaging features together with clinical, laboratory, and biological data to better distinguish asthma from COPD and to identify factors that may predict treatment response. The findings are expected to contribute to more precise and personalized management of chronic airway diseases.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Imaging and multi-omic signatures that differentiate asthma from COPD and predict treatment response (From baseline to last follow-up visit (anticipated up to 12 months after enrollment))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-12-22
Completion: 2027-12-22
Eligibility
Age: 19 Years and older
Sex: ALL
Volunteers: false
Enrollment: 200 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Korea University Guro Hospital
Collaborators: The Korean Academy of Tuberculosis and Respiratory Diseases, Seoul National University Boramae Hospital
Principal Investigators:
  • Sang Hyuk Kim, MD (PRINCIPAL_INVESTIGATOR) - Korea University Guro Hospital
Contact Information
Study Contact:
Sang Hyuk Kim, MD
+82-2-2626-1659
gost702@korea.ac.kr
Clinical Research Office Korea University Guro Hospital
+82-2-2626-1659
kumc.guro.rst@kumc.or.kr
Hyun Woo Lee, MD, PhD
82-2-870-3432
athrunzara86@snu.ac.kr
SMG-SNU Boramae Medical Center
Interventions
N/A
Study Locations (2 sites)
SMG-SNU Boramae Medical Center, Seoul, Dongjak-gu 07061 South Korea
Korea University Guro Hospital, Seoul, Guro-gu 08308 South Korea
Eligibility Criteria
Inclusion Criteria: * Age ≥19 years * COPD group: post-bronchodilator FEV1/FVC \< 0.70 * Asthma group: clinically confirmed diagnosis of asthma by a physician * Able to provide voluntary written informed consent Exclusion Criteria: * Acute exacerbation or active lower respiratory tract infection (e.g., pneumonia) within the past 4 weeks * Pregnancy or breastfeeding * Inability to undergo chest CT (e.g., poor cooperation or severe medical condition) * Refusal to consent to study procedures
Conditions Breast Cancer and Rehabilitation
Phase NA
Enrollment 105
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Breast cancer is one of the most common cancers among women worldwide, with surgery being a primary treatment. However, surgical tumor resection combined with lymph node dissection often leads to upper extremity lymphedema as a complication. This study aims to evaluate the effectiveness of preoperative rehabilitation exercise on upper limb function, lymphedema severity, quality of life, and post-discharge care needs in breast cancer patients undergoing surgery. Participants will be assigned to either an experimental group receiving individualized preoperative rehabilitation exercise instruction or a control group receiving standard clinical nursing education. Outcomes will be measured across seven time points from pre-operation up to one year post-surgery.

Design

Study type: Interventional Phases: Allocation: Non Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: None

Interventions / Regimen

  • Behavioral: Preoperative Upper Limb Rehabilitation Exercise — Individualized instruction and guidance on upper limb rehabilitation exercises starting 1 day prior to surgery to reduce postoperative lymphedema and improve physical function.
  • Other: Standard Nursing Care and Education — Routine clinical nursing education executed preoperatively or on postoperative Day 1 according to standard ward procedures.

Primary Outcomes

  • Postoperative Upper Extremity Lymphedema Severity (Arm Circumference) (Baseline (1 day pre-operation), Postoperative Day 1, Week 2, Week 4, Month 3, Month 6, and Year 1)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-06-01
Completion: 2026-12-31
Eligibility
Age: 20 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 105 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: National Taiwan University Hospital
Contact Information
Study Contact:
Meng-Ping Hsiao
+886-919865349
A00708@ntucc.gov.tw
Meng-Ping Hsiao
+886-919865349
A00708@ntucc.gov.tw
National Taiwan University Hospital Cancer Center
Meng-Ping Hsiao
National Taiwan University Hospital Cancer Center
Interventions
  • Behavioral: Preoperative Upper Limb Rehabilitation Exercise — Individualized instruction and guidance on upper limb rehabilitation exercises starting 1 day prior to surgery to reduce postoperative lymphedema and improve physical function.
  • Other: Standard Nursing Care and Education — Routine clinical nursing education executed preoperatively or on postoperative Day 1 according to standard ward procedures.
Study Locations (2 sites)
National Taiwan University Hospital Cancer Center, Taipei, 106 Taiwan
National Taiwan University Hospital, Taipei, Taiwan
Eligibility Criteria
Inclusion Criteria: * Diagnosed with malignant breast cancer confirmed by post-surgical tissue examination. * Receiving primary surgery, including tumor resection combined with axillary lymph node dissection. * Age 20 years or older. * Conscious, able to communicate in Mandarin or Taiwanese, aware of diagnosis, capable of completing questionnaires and participating in interventions, and signed informed consent. Exclusion Criteria: * Severe cognitive impairment or unaware of diagnosis, unable to complete questionnaires or correctly execute intervention measures. * Patients in the control group who independently schedule outpatient rehabilitation after returning home. * Unable to communicate in Mandarin or Taiwanese. * Undergoing breast reconstruction surgery.
Conditions Type 2 Diabetes
Phase NA
Enrollment 20
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

To conduct a randomized control trial to determine the impact of 6-weeks of blood flow restriction training on immune cell function and bioenergetics in adults living with type 2 diabetes.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Basic Science Masking/blinding: None

Interventions / Regimen

  • Other: Exercise — In both groups participants will complete treadmill walking on 3 days per week for 6 weeks. During the first week participants will walk continuously for 21 minutes during each training session which will be increased to 32 minutes per training session for weeks 2-6. In both groups the treadmill speed and grade will be set to elicit 40-50% heart rate reserve. In the BFR group the cuffs will be inflated based on each participants individualized limb occlusion pressure (LOP). The cuffs will remain inflated for the entire session but will deflate for 1 min every 10 min based on safety recommendations. The percentage of LOP will progressively increase over the course of the intervention. Weeks 1 and 2 will be completed at 60% LOP, after which pressure will increase by 5% each subsequent week, corresponding to 65%, 70%, 75%, and 80% LOP during weeks 3, 4, 5, and 6, respectively.

Primary Outcomes

  • Change in T-cell oxygen consumption rate (OCR) measured before and after the 6-week intervention (0-6 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-02-11
Completion: 2027-12-31
Eligibility
Age: 19 Years and older
Sex: ALL
Volunteers: false
Enrollment: 20 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of British Columbia
Contact Information
Study Contact:
Jonathan P Little, PhD
250-807-9876
jonathan.little@ubc.ca
Jonathan P Little, PhD
250-807-9876
jonathan.little@ubc.ca
University of British Columbia Okanagan
Interventions
  • Other: Exercise — In both groups participants will complete treadmill walking on 3 days per week for 6 weeks. During the first week participants will walk continuously for 21 minutes during each training session which will be increased to 32 minutes per training session for weeks 2-6. In both groups the treadmill speed and grade will be set to elicit 40-50% heart rate reserve. In the BFR group the cuffs will be inflated based on each participants individualized limb occlusion pressure (LOP). The cuffs will remain inflated for the entire session but will deflate for 1 min every 10 min based on safety recommendations. The percentage of LOP will progressively increase over the course of the intervention. Weeks 1 and 2 will be completed at 60% LOP, after which pressure will increase by 5% each subsequent week, corresponding to 65%, 70%, 75%, and 80% LOP during weeks 3, 4, 5, and 6, respectively.
Study Locations (1 sites)
University of British Columbia Okanagan, Kelowna, British Columbia V1V 1V7 Canada
Eligibility Criteria
Inclusion Criteria: A. Aged 19-64 years. B. Diagnosed with type 2 diabetes with current HbA1c 5.7-9.0% C. Completing \<150 minutes of moderate-vigorous physical activity per week. Exclusion Criteria: A. Chronic musculoskeletal condition or recent (within 2 years) cardiovascular event preventing participation in exercise. B. Unstable type 2 diabetes medication of the last 3 months C. Absolute contraindications to BFR (i.e., peripheral vascular disease) D. A self-reported diagnosis of low iron concentrations, anemia, or being treated for these conditions E. A diagnosis of any red blood cell-altering condition (i.e., sickle cell anemia, poikilocytosis) F. Currently living with any cardiovascular disease, which would impact the ability to participate in exercise safely G. Currently prescribed any medication which would impact the ability to use a heart rate monitor to accurately track intensity
Conditions Perimenopause, Perimenopause-Related Dep...
Phase NA
Enrollment 20
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This is a clinical trial aimed to investigate if a novel phytochemical and fibre-rich snack can improve perimenopausal symptoms and well-being in perimenopausal women aged 40-55 and not on hormone replacement therapy. Hypothesis: The investigators hypothesise that the phytochemical and fibre-rich snack will improve perimenopausal symptoms via a gut microbiota mediated mechanism. Main research questions: Does eating the snack every day lower menopause symptoms such as hot flushes, night sweats, mood changes, and sleep problems? Does the snack improve mood, stress, anxiety, sleep, and overall quality of life? Does the snack improve the balance of bacteria in the gut, and could this be part of how it helps symptoms?

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Crossover Primary purpose: Basic Science Masking/blinding: Triple

Interventions / Regimen

  • Dietary Supplement: Functional Snacks — A type of phytochemical and fibre rich snack that created and produced by TulaCode called Cinnamon Granola Bark (50 g per pouch). The snack contains the following ingredients: Amaranth, coconut flakes, chia seeds, pumpkin seeds, sunflower seeds, pecans, brazil nuts, almonds, dates, banana, cold pressed extra virgin olive oil, 100% cocoa mass, cocoa butter, chicory root fibre, cinnamon, cloves, nutmeg, ginger, ground vanilla pod, natural Bourbon vanilla flavouring, salt
  • Other: Placebo Snacks — A type of calorie-matched commercially available chocolate snack, Mini Cornflake Cluster Bites (50 g per pouch). The snack contains the following ingredients: Milk chocolate (60%) (sugar, cocoa butter, cocoa mass, skimmed milk powder, milk fat, lactose (milk), emulsifier (soya lecithin)), corn flakes (40%) (maize, sugar, salt, barley malt extract, dextrose, niacin, iron, vitamin B6, riboflavin, vitamin B1, folic acid, vitamin B12)

Primary Outcomes

  • Changes in menopause rating scale (MRS) of perimenopausal women (Baseline & 4 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-04-24
Completion: 2026-12
Eligibility
Age: 40 Years and older
Sex: FEMALE
Volunteers: true
Enrollment: 20 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: King's College London
Collaborators: Tulā Code Ltd
Principal Investigators:
  • Ana Rodriguez-Mateos, PhD (PRINCIPAL_INVESTIGATOR) - King's College London
Contact Information
Study Contact:
Ana Rodriguez-Mateos, PhD
+44 (0)20 7848 4349
ana.rodriguez-mateos@kcl.ac.uk
Zicheng Zhang, PhD
+44 (0)20 7848 0313
swap@kcl.ac.uk
Zicheng Zhang, PhD
+442078480313
swap@kcl.ac.uk
Metabolic Research Unit (KCL, Waterloo Campus)
Interventions
  • Dietary Supplement: Functional Snacks — A type of phytochemical and fibre rich snack that created and produced by TulaCode called Cinnamon Granola Bark (50 g per pouch). The snack contains the following ingredients: Amaranth, coconut flakes, chia seeds, pumpkin seeds, sunflower seeds, pecans, brazil nuts, almonds, dates, banana, cold pressed extra virgin olive oil, 100% cocoa mass, cocoa butter, chicory root fibre, cinnamon, cloves, nutmeg, ginger, ground vanilla pod, natural Bourbon vanilla flavouring, salt
  • Other: Placebo Snacks — A type of calorie-matched commercially available chocolate snack, Mini Cornflake Cluster Bites (50 g per pouch). The snack contains the following ingredients: Milk chocolate (60%) (sugar, cocoa butter, cocoa mass, skimmed milk powder, milk fat, lactose (milk), emulsifier (soya lecithin)), corn flakes (40%) (maize, sugar, salt, barley malt extract, dextrose, niacin, iron, vitamin B6, riboflavin, vitamin B1, folic acid, vitamin B12)
Study Locations (1 sites)
Metabolic Research Unit (KCL, Waterloo Campus), London, London SE1 9NH United Kingdom
Eligibility Criteria
Inclusion Criteria: * Adults aged 40 to 55 * Score 14 or higher on the Menopause Rating Scale * For intervention purposes, eligible participants are also required to have a mobile phone and be able to read and speak English. Exclusion Criteria: * People who consume more than 15g of fibre a day * People who consume more than 2 cups of coffee or tea a day * People who consume more than 4 portions (portion = 80g) of fruits and vegetables a day * People who do not have any intolerances or allergies to the following: * Any kinds of nuts including tree nuts, peanuts, hazelnuts and coconuts * Chia seeds * Pumpkin seeds * Sunflower seeds * Dates * Gluten * Dairy * Oats * Barley * Soya * People who smoke or vape or have smoked or vaped in the last 2 years * People who consume more than 21 drinks a week or have a history of excess alcohol intake * People with comorbid conditions that may limit participation in the study, such as a history of an acute cardiovascular event, including coronary artery disease, previous myocardial infarction (heart attack), stroke, peripheral artery disease, diabetes mellitus, chronic kidney disease, metabolic syndrome, malignancies, cardiac arrhythmia, renal failure, cardiac failure, uncontrolled hypertension, cancer or major psychiatric or cognitive problems * People receiving drug treatment for lipid metabolisms (e.g., statins) * People with a history of long-term use of medicines known to influence glucose metabolism (e.g., corticosteroids) or aspirin * People taking antihypertensive drugs * People who take antibiotics or bacterial agents (Probiotics) within 1 month * People who take vitamin/dietary supplements within 1 month * Pregnant women, women ready for pregnancy, and nursing mothers * cardiac arrhythmia * renal failure * heart failure (NYHA II-IV) * diabetes mellitus * Malignant disease * People who have participated in a biomedical study within the past 3 months * Women who require hormone replacement therapy during the development of the protocol.
Conditions Mild Cognitive Impairment (MCI), Depress...
Phase NA
Enrollment 45
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study aims to evaluate the effects of repetitive transcranial magnetic stimulation (rTMS) and aerobic exercise on cognitive function and mental health in older adults with mild cognitive impairment (MCI) and comorbid depression. Forty-five participants will be randomly assigned to one of three groups: (1) rTMS alone, (2) rTMS combined with stationary cycling exercise, or (3) sham rTMS combined with stationary cycling exercise. Participants will receive 20 intervention sessions over a 5-week period (4 sessions per week). Outcomes, including cognitive function, depressive symptoms, sleep quality, life satisfaction, self-efficacy, and gait performance, will be assessed at baseline, immediately after completion of the 5-week intervention, and at a 1-month follow-up. The findings may contribute to the development of evidence-based, non-pharmacological interventions for improving cognitive and mental health outcomes in older adults with MCI and comorbid depression.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Device: Repetitive Transcranial Magnetic Stimulation — Active repetitive transcranial magnetic stimulation (rTMS) is delivered over the left dorsolateral prefrontal cortex (DLPFC) using a figure-of-eight coil. Participants receive stimulation sessions 4 times per week for 5 weeks (20 sessions total).
  • Behavioral: Aerobic Exercise — Participants perform 30 minutes of moderate-intensity stationary cycling exercise immediately following rTMS or sham rTMS sessions. Exercise sessions are conducted 4 times per week for 5 weeks (20 sessions total).
  • Device: Sham Repetitive Transcranial Magnetic Stimulation — Sham stimulation is delivered using a figure-of-eight coil positioned at a 90-degree angle relative to the scalp and approximately 3 cm away from the scalp surface to mimic the sensory and auditory experience of active stimulation without producing effective cortical activation. Participants receive sham stimulation sessions 4 times per week for 5 weeks (20 sessions total).

Primary Outcomes

  • Montreal Cognitive Assessment (MoCA) (Baseline through 1-month follow-up (assessed at baseline, immediately after the 5-week intervention, and 1 month after intervention completion))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-03-03
Completion: 2027-12-31
Eligibility
Age: 65 Years and older
Sex: ALL
Volunteers: false
Enrollment: 45 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Cheng-Hsin General Hospital
Principal Investigators:
  • Kai-Chen Wang, MD (PRINCIPAL_INVESTIGATOR) - Cheng-Hsin General Hospital
Contact Information
Study Contact:
Ya-Chu Chan, MS Candidate
+886-983-559-807
aya45285@gmail.com
Ya-Chu Chan, MS Candidate
+886-983-559-807
aya45285@gmail.com
Cheng Hsin General Hospital
Kai-Chen Chan, MD
+886-983-559-807
aya45285@gmail.com
Cheng Hsin General Hospital
Interventions
  • Device: Repetitive Transcranial Magnetic Stimulation — Active repetitive transcranial magnetic stimulation (rTMS) is delivered over the left dorsolateral prefrontal cortex (DLPFC) using a figure-of-eight coil. Participants receive stimulation sessions 4 times per week for 5 weeks (20 sessions total).
  • Behavioral: Aerobic Exercise — Participants perform 30 minutes of moderate-intensity stationary cycling exercise immediately following rTMS or sham rTMS sessions. Exercise sessions are conducted 4 times per week for 5 weeks (20 sessions total).
  • Device: Sham Repetitive Transcranial Magnetic Stimulation — Sham stimulation is delivered using a figure-of-eight coil positioned at a 90-degree angle relative to the scalp and approximately 3 cm away from the scalp surface to mimic the sensory and auditory experience of active stimulation without producing effective cortical activation. Participants receive sham stimulation sessions 4 times per week for 5 weeks (20 sessions total).
Study Locations (1 sites)
Cheng Hsin General Hospital, Taipei, Taipei City 112 Taiwan
Eligibility Criteria
Inclusion Criteria: 1. Aged 65 to 90 years. 2. Diagnosed with mild cognitive impairment (MCI) according to established clinical criteria. 3. Presence of depressive symptoms as determined by clinical assessment and Beck Depression Inventory-II (BDI-II). 4. Able to communicate and follow study instructions. 5. Able to ambulate independently with or without an assistive device. 6. Able to provide written informed consent. Exclusion Criteria: 1. Diagnosis of dementia. 2. History of epilepsy or seizure disorder. 3. Presence of metallic implants, pacemakers, cochlear implants, or other contraindications to transcranial magnetic stimulation. 4. Major neurological disorders, including stroke, Parkinson's disease, traumatic brain injury, or other neurodegenerative diseases. 5. Severe psychiatric disorders other than depression. 6. Severe cardiovascular, musculoskeletal, or medical conditions that preclude participation in aerobic exercise. 7. Severe visual or hearing impairments that interfere with cognitive assessment. 8. Current participation in another intervention study.
Conditions Intrahepatic Cholangiocarcinoma (Icc), L...
Phase NA
Enrollment 30
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this study is to find out whether phycocyanin, a natural protein from spirulina, can help protect the liver and support recovery in adults having part of their liver removed. The study will also look at whether phycocyanin is safe to take.The main questions are: Does phycocyanin reduce liver injury after surgery? Does it help the liver grow back and recover? What side effects or medical problems happen while taking it? Researchers will compare phycocyanin with a placebo, which looks similar but does not contain phycocyanin. About 30 people will take part. Each person will be randomly placed into one of the two groups, and neither the participants nor the researchers will know which treatment each person receives during the study. Participants will: Take 1.5 grams of phycocyanin or placebo every day for 3 weeks before surgery and 3 weeks after surgery Receive the usual care for liver surgery Give blood and stool samples before and after treatment Allow researchers to study a small piece of liver tissue removed during surgery Return for follow-up for up to 90 days after surgery The samples will be used to check liver function, inflammation, gut bacteria, and changes linked to liver healing. Possible side effects include an allergic reaction or stomach discomfort. The study has been approved by an ethics committee.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Dietary Supplement: Phycocyanin — Participants will take 1.5 grams of phycocyanin by mouth once daily for 3 weeks before partial hepatectomy and for 3 weeks after surgery. Phycocyanin is a natural protein from spirulina.
  • Dietary Supplement: Maltodextrin — Participants will take 1.5 grams of maltodextrin placebo by mouth once daily for 3 weeks before partial hepatectomy and for 3 weeks after surgery. The placebo does not contain phycocyanin.

Primary Outcomes

  • Change in Serum Aspartate Aminotransferase (AST) Level (Baseline and Week 3 after surgery)
  • Change in Serum Alanine Aminotransferase (ALT) Level (Baseline and Week 3 after surgery)
  • Change in Serum Total Bilirubin (TBIL) Level (Baseline and Week 3 after surgery)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-06-01
Completion: 2029-05-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 30 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Second Affiliated Hospital, Zhejiang University, School of Medicine
Contact Information
Study Contact:
Xiaopeng Cai
+86 18768161626
cxpeng@zju.edu.cn
Xiaopeng Cai
+86 18768161626
cxpeng@zju.edu.cn
The Second Affiliated Hospital of Zhejiang University
Interventions
  • Dietary Supplement: Phycocyanin — Participants will take 1.5 grams of phycocyanin by mouth once daily for 3 weeks before partial hepatectomy and for 3 weeks after surgery. Phycocyanin is a natural protein from spirulina.
  • Dietary Supplement: Maltodextrin — Participants will take 1.5 grams of maltodextrin placebo by mouth once daily for 3 weeks before partial hepatectomy and for 3 weeks after surgery. The placebo does not contain phycocyanin.
Study Locations (1 sites)
The Second Affiliated Hospital of Zhejiang University, Hangzhou, Zhejiang China
Eligibility Criteria
Inclusion Criteria: * Diagnosis of intrahepatic cholangiocarcinoma * Child-Pugh class A liver function * Planned neoadjuvant treatment with gemcitabine plus oxaliplatin, lenvatinib, and a PD-1 inhibitor * Planned anatomical hemihepatectomy with an expected future liver remnant greater than 40% * Age 18 to 75 years * Willing and able to participate and provide written informed consent * No acute illness or significant worsening of symptoms within 4 weeks before enrollment Exclusion Criteria: * Serious coexisting medical conditions * Known allergy to phycocyanin * Other malignant tumors * Previous liver resection * History of severe psychiatric illness that may affect treatment adherence